Ruth Plummer

Ruth Plummer

UNVERIFIED PROFILE

Are you Ruth Plummer?   Register this Author

Register author
Ruth Plummer

Ruth Plummer

Publications by authors named "Ruth Plummer"

Are you Ruth Plummer?   Register this Author

82Publications

2047Reads

29Profile Views

Chronic cardiovascular toxicity in the older oncology patient population.

J Geriatr Oncol 2019 Sep 5;10(5):685-689. Epub 2019 Feb 5.

Northern Institute for Cancer Research (NICR), Paul O'Gorman Building, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne NE2 4HH, UK; Department of Cardiology, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne NE7 7DN, UK. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jgo.2019.01.018DOI Listing
September 2019

Reply to E. Hindié and K.R. Hess.

J Clin Oncol 2019 May 2;37(15):1356-1358. Epub 2019 Apr 2.

Georgina V. Long, MD, PhD, Melanoma Institute Australia, The University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, NSW, Australia; Reinhard Dummer, MD, University Hospital Zürich Skin Cancer Center, Zürich, Switzerland; Dirk Schadendorf, MD, PhD, University Hospital Essen, Essen, Germany, and German Cancer Consortium, Heidelberg, Germany; Mario Santinami, MD, Fondazione Istituto Nazionale Tumori, Milan, Italy; Victoria Atkinson, MD, Princess Alexandra Hospital, Gallipoli Medical Research Foundation, and University of Queensland, Brisbane, QLD, Australia; Mario Mandalà, MD, Papa Giovanni XXIII Cancer Center Hospital, Bergamo, Italy; Vanna Chiarion-Sileni, MD, Veneto Institute of Oncology-Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy; James Larkin, MD, PhD, Royal Marsden National Health Service Foundation Trust, London, United Kingdom; Marta Nyakas, MD, Oslo University Hospital, Oslo, Norway; Caroline Dutriaux, MD, Centre Hospitalier Universitaire de Bordeaux, Hôpital Saint-André, Bordeaux, France; Andrew Haydon, MD, PhD, The Alfred Hospital, Melbourne, VIC, Australia; Caroline Robert, MD, PhD, Institute Gustave Roussy, Paris, France; Laurent Mortier, MD, PhD, Université de Lille, Institut National de la Santé et de la Recherche Médicale U 1189, Centre Hospitalier Universitaire Lille, Lille, France; Jacob Schachter, MD, PhD, Sheba Medical Center, Tel HaShomer, Israel, and Tel Aviv University, Tel Aviv, Israel; Thierry Lesimple, MD, MSc, Centre Eugène Marquis, Rennes, France; Ruth Plummer, MD, PhD, Freeman Hospital and Newcastle University, Newcastle upon Tyne, United Kingdom; Kohinoor Dasgupta, PhD, Novartis Healthcare, Hyderabad, India; Tomas Haas, PhD, Novartis AG, Basel, Switzerland; Mark Shilkrut, MD, PhD and Eduard Gasal, MD, Novartis Pharmaceuticals, East Hanover, NJ; Richard Kefford, MD, PhD, Melanoma Institute Australia, The University of Sydney, Macquarie University, and Westmead Hospital, Sydney, NSW, Australia; John M. Kirkwood, MD, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA; and Axel Hauschild, MD, University Hospital Schleswig-Holstein, Kiel, Germany.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.19.00004
Publisher Site
http://dx.doi.org/10.1200/JCO.19.00004DOI Listing
May 2019

BRAF Wild-type, PTEN Mutant Malignant Uveal Melanoma Arising Within a Mature Ovarian Teratoma: A Case Report and Review of the Literature.

Int J Gynecol Pathol 2019 May 30. Epub 2019 May 30.

Department of Gynaecological Pathology, Queen Elizabeth Hospital, Gateshead (K.L., A.R.) Department of Histopathology, Cumberland Infirmary, Carlisle (F.Y.) Northern Centre for Cancer Care, Freeman Hospital, Newcastle Upon Tyne (A.K., N.C., R.P.) Northern Institute for Cancer Research, Newcastle University, Framlington Place, Newcastle (R.P., R.L.O.) Northern Gynaecological Oncology Centre, Queen Elizabeth Hospital, Gateshead (R.L.O.), UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PGP.0000000000000614DOI Listing
May 2019

The DNA Damaging Revolution: PARP Inhibitors and Beyond.

Am Soc Clin Oncol Educ Book 2019 Jan 17;39:185-195. Epub 2019 May 17.

4 Weston Park Cancer Centre, Department of Oncology and Metabolism, University of Sheffield, Sheffield, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_238473DOI Listing
January 2019

Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III Melanoma.

J Clin Oncol 2018 Oct 22:JCO1801219. Epub 2018 Oct 22.

Axel Hauschild, University Hospital Schleswig-Holstein, Kiel; Dirk Schadendorf, University Hospital Essen, Essen; German Cancer Consortium, Heidelberg, Germany; Reinhard Dummer, University Hospital Zürich Skin Cancer Center, Zürich; Tomas Haas, Novartis AG, Basel, Switzerland; Mario Santinami, Fondazione Istituto Nazionale Tumori, Milan; Mario Mandalà, Papa Giovanni XXIII Cancer Center Hospital, Bergamo; Vanna Chiarion-Sileni, Veneto Institute of Oncology-Istituto di Ricovero e Cura a Carattere Scientifico, Padova, Italy; Victoria Atkinson, Princess Alexandra Hospital; Gallipoli Medical Research Foundation; University of Queensland, Brisbane, Queensland; Andrew Haydon, The Alfred Hospital, Melbourne, Victoria; Richard Kefford, Macquarie University; Westmead Hospital; Richard Kefford and Georgina V. Long, Melanoma Institute Australia; University of Sydney; Royal North Shore and Mater Hospitals, Sydney, New South Wales, Australia; James Larkin, Royal Marsden National Health Service Foundation Trust, London; Ruth Plummer, Freeman Hospital and Newcastle University, Newcastle upon Tyne, United Kingdom; Marta Nyakas, Oslo University Hospital, Oslo, Norway; Caroline Dutriaux, Centre Hospitalier Universitaire de Bordeaux, Hôpital Saint-André, Bordeaux; Caroline Robert, Institute Gustave Roussy, Paris; Laurent Mortier, Université de Lille, Institut National de la Santé et de la Recherche Médicale U1189, Centre Hospitalier Universitaire de sa Region Lille, Lille; Thierry Lesimple, Centre Eugène Marquis, Rennes, France; Jacob Schachter, Sheba Medical Center, Tel Hashomer; Tel Aviv University, Tel Aviv, Israel; Kohinoor Dasgupta, Novartis Healthcare, Hyderabad, India; Mark Shilkrut and Eduard Gasal, Novartis Pharmaceuticals Corporation, East Hanover, NJ; and John M. Kirkwood, UPMC Hillman Cancer Center; University of Pittsburgh, Pittsburgh, PA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.18.01219
Publisher Site
http://dx.doi.org/10.1200/JCO.18.01219DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6286159PMC
October 2018

The Effect of Food or Omeprazole on the Pharmacokinetics of Osimertinib in Patients With Non-Small-Cell Lung Cancer and in Healthy Volunteers.

J Clin Pharmacol 2018 04 26;58(4):474-484. Epub 2017 Nov 26.

Northern Centre for Cancer Care, Freeman Hospital, Freeman Road, High Heaton, Newcastle upon Tyne, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcph.1035DOI Listing
April 2018

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.

N Engl J Med 2017 11 10;377(19):1813-1823. Epub 2017 Sep 10.

From the Melanoma Institute Australia, University of Sydney, Royal North Shore and Mater Hospitals (G.V.L.), and Macquarie University, Melanoma Institute Australia, University of Sydney, and Westmead Hospital (R.K.), Sydney, Princess Alexandra Hospital, Gallipoli Medical Research Foundation, University of Queensland, Brisbane (V.A.), and Alfred Hospital, Melbourne, VIC (A. Haydon) - all in Australia; University Hospital Schleswig-Holstein, Kiel (A. Hauschild), and University Hospital Essen, Essen, and the German Cancer Consortium, Heidelberg (D.S.) - all in Germany; Fondazione Istituto Nazionale Tumori, Milan (M.S.), Papa Giovanni XXIII Cancer Center Hospital, Bergamo (M.M.), and the Melanoma Oncology Unit, Veneto Oncology Institute, Padua (V.C.-S.) - all in Italy; Rikshospitalet-Radiumhospitalet, Oslo (M.N.); Centre Hospitalier Universitaire de Bordeaux, Hôpital Saint-André, Bordeaux (C.D.), Institute Gustave Roussy, Paris (C.R.), Université de Lille, INSERM Unité 1189, Centre Hospitalier Régional Universitaire de Lille, Lille (L.M.), and the Medical Oncology Department, Centre Eugène Marquis, Rennes (T.L.) - all in France; Ella Institute for Melanoma, Sheba Medical Center, Tel Hashomer, Israel (J.S.); Royal Marsden NHS Foundation Trust, London (J. Larkin), and Northern Centre for Cancer Care, Freeman Hospital, Newcastle upon Tyne (R.P.) - both in the United Kingdom; Novartis Pharmaceuticals, East Hanover, NJ (R.J., P.Z., B.M., J. Legos); University Hospital Zürich Skin Cancer Center, Zurich, Switzerland (R.D.); and the Melanoma Program, Hillman UPMC Cancer Center, University of Pittsburgh, Pittsburgh (J.M.K.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1708539
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1708539DOI Listing
November 2017

Tremelimumab-Induced Graves Hyperthyroidism.

Eur Thyroid J 2017 Jul 14;6(3):167-170. Epub 2017 Mar 14.

Institute of Genetic Medicine, International Centre for Life, Newcastle upon Tyne, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000464285DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5527187PMC
July 2017

Managing adverse events associated with vismodegib in the treatment of basal cell carcinoma.

Future Oncol 2017 Jan 19;13(2):175-184. Epub 2016 Sep 19.

Salford Royal Hospital, Stott Lane, Salford, M6 8HD, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2016-0296DOI Listing
January 2017

A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours.

Eur J Cancer 2016 11 28;68:1-10. Epub 2016 Sep 28.

Northern Institute for Cancer Research, Paul O'Gorman Building, Medical School, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK; Northern Centre for Cancer Care, Newcastle Freeman Hospital, Newcastle upon Tyne, NE7 7DN, UK. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2016.08.026DOI Listing
November 2016

Imagestream detection and characterisation of circulating tumour cells - A liquid biopsy for hepatocellular carcinoma?

J Hepatol 2016 08 27;65(2):305-13. Epub 2016 Apr 27.

Northern Institute for Cancer Research, Newcastle University, Newcastle-upon-Tyne, UK; The Liver Group, Department of Medicine, Freeman Hospital, Newcastle-upon-Tyne Hospitals, NHS Foundation Trust, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2016.04.014DOI Listing
August 2016

mTORC1 and DNA-PKcs as novel molecular determinants of sensitivity to Chk1 inhibition.

Mol Oncol 2016 Jan 25;10(1):101-12. Epub 2015 Aug 25.

Newcastle University, Northern Institute for Cancer Research, Newcastle upon Tyne, NE2 4HH, UK. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.molonc.2015.08.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5528927PMC
January 2016

Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients.

Melanoma Res 2015 Oct;25(5):432-42

aDepartment of Oncology bCambridge Cancer Trials Centre, Cambridge Clinical Trials Unit - Cancer Theme, Cambridge University Hospitals NHS Foundation Trust, Cambridge cSouthampton Experimental Cancer Medicine Center, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton dDepartment of Medical Oncology, The Christie, Manchester eDepartment of Medicine, Royal Marsden NHS Foundation Trust, London fOxford NIHR Biomedical Research Centre, Oxford gDepartment of Medical Oncology, Mount Vernon Hospital, Northwood hDepartment of Medical Oncology, Velindre Cancer Centre, Cardiff iNorthern Centre for Cancer Care, Newcastle upon Tyne jDirectorate of Haematology and Oncology, Guy's and St. Thomas' NHS Foundation Trust, London kDepartment of Medical Oncology, Royal Wolverhampton Hospitals lDepartment of Medical Oncology, Royal Preston Hospital mClinical Oncology, Norfolk and Norwich University Hospital nDivision of Clinical Sciences, St George's Hospital Medical School, London oDepartment of Oncology, Castle Hill Hospital, Hull pSheffield Experimental Cancer Medicine Centre, University of Sheffield, Weston Park Hospital, Sheffield qClinical Oncology Department, Royal Cornwall Hospitals rSt. James's Institute of Oncology, St. James's University Hospital, Leeds, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0000000000000185DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4560270PMC
October 2015

PARP inhibitors in ovarian and other cancers.

Authors:
Ruth Plummer

Clin Adv Hematol Oncol 2015 May;13(5):285-7

Newcastle University, Newcastle upon Tyne, United Kingdom.

View Article

Download full-text PDF

Source
May 2015

PARP activity in peripheral blood lymphocytes as a predictive biomarker for PARP inhibition in tumor tissues - A population pharmacokinetic/pharmacodynamic analysis of rucaparib.

Clin Pharmacol Drug Dev 2015 03 26;4(2):89-98. Epub 2015 Jan 26.

Northern Institute for Cancer Research, Medical School, Newcastle University, Newcastle Upon Tyne, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cpdd.176DOI Listing
March 2015

A multicenter phase I study of pazopanib in combination with paclitaxel in first-line treatment of patients with advanced solid tumors.

Mol Cancer Ther 2015 Feb 10;14(2):461-9. Epub 2014 Dec 10.

Division of Medical Oncology and Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-14-0431DOI Listing
February 2015

Effect of erlotinib on CYP3A activity, evaluated in vitro and by dual probes in patients with cancer.

Anticancer Drugs 2014 Aug;25(7):832-40

aNorthern Centre for Cancer Care, Freeman Hospital, Newcastle upon Tyne bCancer Research UK Clinical Centre, Leeds Institute of Molecular Medicine, St James's Institute of Oncology, Leeds cChristie Hospital NHS Foundation Trust, University of Manchester, Manchester, UK dHoffmann-La Roche Inc., Nutley, New Jersey eGenentech Inc., South San Francisco, California fOSI Pharmaceuticals Inc., Boulder, CO, USA gHoffmann-La Roche Ltd., Basel, Switzerland.

View Article

Download full-text PDF

Source
http://pdfs.journals.lww.com/anti-cancerdrugs/2014/08000/Eff
Web Search
http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:land
Publisher Site
http://dx.doi.org/10.1097/CAD.0000000000000099DOI Listing
August 2014

Vemurafenib for the treatment of locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma: a NICE single technology appraisal.

Pharmacoeconomics 2013 Dec;31(12):1121-9

Liverpool Reviews and Implementation Group, University of Liverpool, Whelan Building, Brownlow Hill, Liverpool, L69 3GB, UK,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40273-013-0094-xDOI Listing
December 2013

A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation.

Cancer Chemother Pharmacol 2013 May 20;71(5):1191-9. Epub 2013 Feb 20.

Institute for Cancer Research, Paul O'Gorman Building, Newcastle University, Framlington Place, Newcastle upon Tyne NE2 4HH, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-013-2113-1DOI Listing
May 2013

A Phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumors.

Cancer Chemother Pharmacol 2013 Jan 11;71(1):93-101. Epub 2012 Oct 11.

Sir Bobby Robson Cancer Trials Research Centre, Northern Centre for Cancer Care, Newcastle upon Tyne, UK.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00280-012-1982-z
Publisher Site
http://dx.doi.org/10.1007/s00280-012-1982-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3535414PMC
January 2013

PARP inhibitors.

Authors:
Ruth Plummer

Clin Adv Hematol Oncol 2012 May;10(5):322-3

Newcastle University, Newcastle upon Tyne, United Kingdom.

View Article

Download full-text PDF

Source
May 2012

Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy.

Cancer Immunol Immunother 2012 Jan 11;61(1):41-8. Epub 2011 Aug 11.

Medical Oncology and Immunotherapy Unit, University Hospital of Siena, Istituto Toscano Tumori, Strada delle Scotte, 53100 Siena, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-011-1089-0DOI Listing
January 2012

Androgen receptor expression is a biological marker for androgen sensitivity in high grade serous epithelial ovarian cancer.

Gynecol Oncol 2012 Jan 15;124(1):142-7. Epub 2011 Oct 15.

Northern Gynaecological Oncology Centre, Queen Elizabeth Hospital, Gateshead, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2011.09.004DOI Listing
January 2012

Phase I study of weekly plitidepsin as 1-hour infusion combined with carboplatin in patients with advanced solid tumors or lymphomas.

Invest New Drugs 2011 Dec 10;29(6):1406-13. Epub 2010 Jul 10.

Instituto Catalán de Oncología, Ctra. Gran Vía, s/n, L'Hospitalet de Llobregat, 08907, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-010-9488-1DOI Listing
December 2011

Targeting the DNA double strand break repair machinery in prostate cancer.

PLoS One 2011 23;6(5):e20311. Epub 2011 May 23.

The Northern Institute for Cancer Research, Medical School, Newcastle University, Newcastle Upon Tyne, United Kingdom.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0020311PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3100351PMC
September 2011

Poly(ADP-ribose) polymerase inhibition: a new direction for BRCA and triple-negative breast cancer?

Authors:
Ruth Plummer

Breast Cancer Res 2011 Aug 16;13(4):218. Epub 2011 Aug 16.

Northern Institute for Cancer Research, Newcastle University, Paul O'Gorman Building, Framlington Place, Newcastle upon Tyne, NE2 4HH, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/bcr2877DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3236327PMC
August 2011

Progress in the function and regulation of ADP-Ribosylation.

Sci Signal 2011 May 24;4(174):mr5. Epub 2011 May 24.

Institute of Veterinary Biochemistry and Molecular Biology, University of Zurich, Winterthurerstrasse, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1126/scisignal.2001645DOI Listing
May 2011

Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors.

J Clin Oncol 2010 Sep 2;28(25):3965-72. Epub 2010 Aug 2.

Drug Development Unit, the Royal Marsden National Health Service Foundation Trust, and The Institute of Cancer Research, Sutton, Surrey, United Kingdom.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2009.26.7278
Publisher Site
http://dx.doi.org/10.1200/JCO.2009.26.7278DOI Listing
September 2010

Perspective on the pipeline of drugs being developed with modulation of DNA damage as a target.

Authors:
Ruth Plummer

Clin Cancer Res 2010 Sep 7;16(18):4527-31. Epub 2010 Sep 7.

Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-10-0984DOI Listing
September 2010

Extraosseous pericardial Ewing's sarcoma.

J Clin Oncol 2010 Feb 16;28(4):e48-50. Epub 2009 Nov 16.

Department of Medical Oncology, Northern Centre for Cancer Care, Freeman Hospital, Newcastle upon Tyne, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2009.23.7487DOI Listing
February 2010

The emerging potential of poly(ADP-ribose) polymerase inhibitors in the treatment of breast cancer.

Curr Opin Obstet Gynecol 2010 Feb;22(1):67-71

Northern Institute for Cancer Research, Paul O'Gorman Building, Newcastle University, Framlington Place, Newcastle upon Tyne, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/GCO.0b013e328334ff57DOI Listing
February 2010

PARP inhibitors in cancer therapy: two modes of attack on the cancer cell widening the clinical applications.

Drug Resist Updat 2009 Dec 25;12(6):153-6. Epub 2009 Nov 25.

Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.drup.2009.10.001DOI Listing
December 2009

Mechanisms of chemoresistance to alkylating agents in malignant glioma.

Clin Cancer Res 2008 May;14(10):2900-8

Department of Radiation Oncology and Pathology, Mayo Clinic, Rochester, Minnesota 55905, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-07-1719DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2430468PMC
May 2008

Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma.

J Clin Oncol 2002 Aug;20(16):3533-44

Department of Medical Oncology, Northern Centre for Cancer Treatment, Newcastle General Hospital, Westgate Road, Newcastle Upon Tyne NE4 6BE, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2002.10.073DOI Listing
August 2002

Salmonella Contamination of Retail Chicken Products Sold in the UK.

J Food Prot 1995 Aug;58(8):843-846

Department of Applied Biochemistry & Food Science, University of Nottingham, Sutton Bonington Campus, Loughborough, Leicestershire, LE12 SRD, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4315/0362-028X-58.8.843DOI Listing
August 1995